Miguel Lanz, MD
Allergy · Coral Gables, FLNPI 1710034129
Payments from drug & device makers
Across 1,325 payments — averaging $1035.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$465K
- Regeneron$300K
- Sanofi$264K
- Regeneron Healthcare Solutions, Inc.$102K
- Optinose US, Inc.$87K
- Genentech, Inc.$87K
- plus $68K from 19 others
Across 11 payments — averaging $23,275 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$235K
- Optinose US, Inc.$11K
- Novartis$8K
- Regeneron$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 358 | $465,177 |
| Regeneron | 362 | $300,145 |
| Sanofi | 264 | $263,517 |
| Regeneron Healthcare Solutions, Inc. | 142 | $102,021 |
| Optinose US, Inc. | 33 | $86,695 |
| Genentech, Inc. | 16 | $86,624 |
| Astrazeneca UK Limited | 14 | $18,721 |
| Amgen | 13 | $13,748 |
| Novartis | 30 | $11,734 |
| Genentech USA, Inc. | 16 | $7,160 |
| Grifols USA, LLC | 9 | $5,927 |
| Alk-abello, Inc | 19 | $3,275 |
| Chiesi USA, Inc. | 2 | $2,289 |
| Astrazeneca AB | 10 | $1,459 |
| Blueprint Medicines Corporation | 1 | $1,260 |
| Sanofi-aventis U.S. LLC | 15 | $1,124 |
| GSK | 9 | $340 |
| Galderma Laboratories, L.p. | 1 | $135 |
| Circassia Inc. | 2 | $125 |
| Lilly USA, LLC | 2 | $76 |
| Greer Laboratories, Inc. | 1 | $72 |
| Pfizer | 2 | $53 |
| Teva Pharmaceuticals USA, Inc. | 1 | $42 |
| Merck | 2 | $34 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $24 |
How this compares
$1,371,779 in reported general payments places this provider in the 95th percentile of 56 allergy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy in Coral Gables
- Hugh WindomSarasota$3.6M
- Brett StanalandNaples$575K
- Alan KoterbaNorth Palm Beach$367K
- David RoseEglin Afb$253K
- Shahid RandhawaFort Lauderdale$91K
- Carlos PiniellaMiami$61K
- Pavana BeerelliRockledge$61K
- Patrick de MarcoOrange Park$23K
- Mark MinorMelbourne$21K
- Brian WilsonTallahassee$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.